Kura Oncology Logo
Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
January 30, 2024 07:00 ET | Kura Oncology, Inc.
– No differentiation syndrome events reported – – 100% CR rate with 7+3 in newly diagnosed NPM1-m and KMT2A-r AML – – 56% CR/CRh with ven/aza in menin inhibitor naïve patients with R/R AML – – 80%...
22157.jpg
Hemato Oncology Testing Market Anticipated to Surge Amid Technological Innovations and Increased Cancer Prevalence
January 22, 2024 21:23 ET | Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Hemato Oncology Testing Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The latest comprehensive research on...
Aptose Biosciences Inc. logo
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
December 09, 2023 18:30 ET | Aptose Biosciences, Inc.
ASH Oral Presentation: Complete Response Data from the Ongoing APTIVATE Phase 1/2 Study of Tuspetinib (TUS) in R/R AML Patients
Logo.jpg
Acute Myeloid Leukemia Market To Reach USD 5.1 Billion By 2032
December 06, 2023 06:30 ET | DataHorizzon Research
Fort Collins, Colorado, Dec. 06, 2023 (GLOBE NEWSWIRE) -- According to DataHorizzon Research, The Acute Myeloid Leukemia Market size is expected to grow from USD 1.7 Billion in 2023 to USD 5.1...
Kura Oncology Logo
Kura Oncology Reports Third Quarter 2023 Financial Results
November 02, 2023 16:01 ET | Kura Oncology, Inc.
– Completion of enrollment in KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant AML expected by mid-2024 – – Preliminary data from 20 patients in KOMET-007 combination trial of...
Kura Oncology Logo
Kura Oncology to Participate in Three Upcoming Investor Conferences
October 30, 2023 07:30 ET | Kura Oncology, Inc.
SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Logo.png
Acute Myeloid Leukemia Market Size and Share to Rise by 2032, Predicts DelveInsight | Key Companies - Chimerix, GlycoMimetics, Arog, Delta-Fly, Jasper, Jazz, Daiichi Sankyo, Amgen, AbbVie, Merck, Eli Lilly
August 07, 2023 13:00 ET | DelveInsight Business Research LLP
New York, USA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Acute Myeloid Leukemia Market Size and Share to Rise by 2032, Predicts DelveInsight | Key Companies - Chimerix, GlycoMimetics, Arog, Delta-Fly,...
logo-header-min.png
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
August 07, 2023 07:00 ET | Marker Therapeutics
HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Kura Oncology Logo
Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
June 14, 2023 07:00 ET | Kura Oncology, Inc.
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Logo
Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants
June 13, 2023 16:01 ET | Kura Oncology, Inc.
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...